Key result
Imidaprilat significantly decreased oxidized LDL-induced foam cell formation in THP-1 macrophages by attenuating MMP-9 activity.
Why the study?
Does imidaprilat reduce oxidized LDL-mediated foam-cell formation in THP-1 macrophages?
Does imidaprilat reduce oxidized LDL-mediated foam-cell formation in THP-1 macrophages?
Imidaprilat reduces OxLDL-triggered foam-cell formation in macrophages by inhibiting MMP-9 activity, highlighting a potential anti-atherosclerotic mechanism of ACE inhibitors.
Hypothesis-generating for ACE inhibitor pleiotropy in atherosclerosis; leaves open translation to human disease.
AIM: Angiotensin-converting enzyme inhibitors (ACEIs) have been shown to block matrix metalloproteinase (MMP)-9 activity, which plays a role in atherogenesis. MMP-9 activity of macrophages is increased during foam cell formation. To investigate the contribution of ACEIs to foam cell formation, we studied the effects of an ACEI, imidaprilat, on THP-1 macrophages and the underlying molecular mechanisms in vitro. METHODS AND RESULTS: Pre-treatment of THP-1 macrophages with imidaprilat (100 nmol/L, 4 hours) significantly decreased foam cell formation induced by oxidized LDL (OxLDL). Imidaprilat reduced the protein level of MMP-9 in THP-1 macrophages and attenuated OxLDL-induced MMP-9 activity in the culture supernatants. Indeed, pretreatment of THP-1 macrophages with an MMP-2/9 inhibitor (20 micromol/L, 4 hours) attenuated OxLDL-induced foam-cell formation. Imidaprilat or the MMP-2/9 inhibitor blocked OxLDL-induced expressions of LOX-1 and scavenger receptor-A (SR-A), but not that of CD36, in THP-1 macrophages. In addition, OxLDL-induced activation of p38 mitogen-activated protein kinase (MAPK) and ERK, but not JNK, was blunted by imidaprilat or the MMP-2/9 inhibitor. Finally, siRNA against MMP-9 inhibited foam cell formation as well as lipid accumulation in THP-1 macrophages. CONCLUSION: These findings suggest that imidaprilat reduces OxLDL-triggered foam-cell formation in THP-1 macrophages via modulation of MMP-9 activity and may indicate a novel antiinflamma-tory mechanism of imidaprilat in atherogenesis.
No takes yet. Share an insight, caveat, or question.
Kojima et al. (2010) studied Atherosclerosis (Foam cell formation). Imidaprilat vs. OxLDL alone was evaluated on OxLDL-induced foam cell formation (lipid accumulation) (p=<0.01). Imidaprilat significantly decreased oxidized LDL-induced foam cell formation in THP-1 macrophages by attenuating MMP-9 activity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: